GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/IBD/ultraprocessed grains and IBD

ultraprocessed grains and IBD

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated December 1, 2025

Quick Answer

The relationship between ultraprocessed grains and inflammatory bowel disease (IBD) has been examined in the context of the Prospective Urban Rural Epidemiology (PURE) study. This study highlights a significant association between the consumption of ultraprocessed grains and an increased risk of developing IBD, which includes conditions such as Crohn's disease and ulcerative colitis.


The relationship between ultraprocessed grains and inflammatory bowel disease (IBD) has been examined in the context of the Prospective Urban Rural Epidemiology (PURE) study. This study highlights a significant association between the consumption of ultraprocessed grains and an increased risk of developing IBD, which includes conditions such as Crohn's disease and ulcerative colitis. Below is a detailed explanation based on the findings:

### What Are Ultraprocessed Grains?

Ultraprocessed grains are a category of foods that undergo extensive refining processes. These processes often remove beneficial nutrients, such as fiber, and incorporate additives like preservatives, flavor enhancers, and texturizers to improve shelf life, taste, and texture. Examples include white bread, certain breakfast cereals, instant noodles, and other refined grain products commonly found in Western diets.

### The PURE Study Findings

The PURE study evaluated dietary habits across diverse populations using long-term, multinational cohort data. Key findings include:

1. **Increased Risk of IBD**: Higher consumption of ultraprocessed grains was associated with a greater risk of developing IBD. This relationship remained significant even after adjusting for major lifestyle and demographic factors.

2. **Protective Effect of Less Processed Grains**: In contrast, consuming less processed grain staples, such as fresh bread and rice, was linked to a reduced risk of IBD.

3. **Broader Implications for Ultraprocessed Foods**: The study also observed that diets high in overall ultraprocessed foods, not just grains, were associated with negative impacts on intestinal health, further emphasizing the role of food processing levels.

### Mechanisms Linking Ultraprocessed Grains to IBD

The study suggests several mechanisms through which ultraprocessed grains may contribute to intestinal inflammation and increase IBD risk:

1. **Altered Gut Microbiota**: Ultraprocessed grains may disrupt the gut microbiome, leading to imbalances that promote inflammation.

2. **Reduced Fiber Intake**: The refining process removes dietary fiber, which is essential for maintaining gut health and reducing inflammation.

3. **Exposure to Food Additives**: Additives in ultraprocessed grains, such as emulsifiers and artificial flavors, may irritate the intestinal lining, exacerbate inflammation, or negatively affect gut bacteria.

### Recommendations

The study's authors recommend minimizing the consumption of ultraprocessed grains as part of a healthy dietary pattern to reduce the risk of IBD. Instead, individuals are encouraged to prioritize less processed grain options and whole foods that retain their natural fiber and nutrient content. Additionally, further research is suggested to pinpoint the specific components of ultraprocessed grains responsible for the increased risk of IBD.

### Conclusion

Ultraprocessed grains are linked to a heightened risk of developing IBD due to their potential to disrupt gut health through mechanisms such as microbiota alterations, reduced fiber levels, and exposure to additives. Adopting a diet that emphasizes whole, minimally processed grains can play a protective role against IBD and improve overall intestinal health.

Related Q&A

IBD Across Ethnicities: Gastroenterology | July 2026

Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...

Moving Beyond the "Wait to Fail" Strategy in ASUC: FG | 2026

Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...

FMT in Ulcerative Colitis: JGH | July 2026

Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...

Engineering Immune Cell Therapies for IBD: Nat Re Gastroe & Hepato | June 2026

Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...

Real-World IBD Patients Rarely Meet Clinical Trial Criteria: AJG | June 2026

Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...

Mirikizumab in Ulcerative Colitis: JCC | June 2026

Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer